<DOC>
	<DOCNO>NCT02028416</DOCNO>
	<brief_summary>Acquired Aplastic anemia one frequent reason bone marrow failure East ( Pakistan ) . - The first treatment option Allogenic Bone Marrow transplantation expansive treatment option also require full match HLA identical donor , hence hardly 25 % affect patient get opportunity BMT . - The second line treatment option caters large chunk patient ( severe non-severe AA ) along lack HLA identical donor . Previously many protocol use past ATG+CsA Treatment , treatment protocol especially address two different regimen ATG study efficacy , durability long-term effect . Following dos would use : - CsA+ATG @ 10mg/kg 3 day - CsA+ATG @ 10mg/kg 5 day</brief_summary>
	<brief_title>Comparison Two Different Doses Rabbit ATG-Fresenius With Cyclosporin Treatment Acquired Aplastic Anaemia</brief_title>
	<detailed_description>Aplastic Anaemia ( AA ) characterize pancytopenia hypo-cellular bone marrow absence dysplasia , infiltration fibrosis . The recommended first-line treatment option include Allogenic Bone Marrow Transplantation HLA match sibling donor . However , due non-availability HLA match identical sibling donor due co-morbids age , second choice treatment Anti Thymocyte Globulin ( ATG ) Cyclosporin ( CsA ) . Rabbit ATG ( Fresenius ) never test treatment aplastic anaemia Pakistani population . We propose investigator initiated trial compare two different protocol Rabbit ATG-Fresenius , 10mg/kg 3 day 10mg/kg 5 day along CsA Pakistani patient suffer AA . The subject Non-severe ( NSAA ) severe AA ( SAA ) eligible candidate Allogenic Bone Marrow Transplantation . Patients randomize two equal arm biological characteristic . Both arm treat ATG-Fresenius CsA dose two different duration treatment . They later continue CsA least 12 month response achieve , taper slowly next 6 month . The primary end point document number dos require two dose schedule produce response , achieve nadir absolute lymphocyte count 200 cmm . Secondary endpoint short term safety ATG-Fresenius , change absolute neutrophil count baseline arm , change platelet count baseline , change absolute reticulocyte count , Number blood unit require till 8 week 26 week , Number platelet dos require till 8 week 26 week , relapse , response rate 6 12 month , clonal evolution PNH , myelodysplasia acute leukaemia . Long-course CsA assess separately efficacy reduce late event relapse evolution comparison historical control data .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>. Severe aplastic anemia characterize : Bone marrow cellularity &lt; 30 % ( exclude lymphocyte ) AND At least two follow : . Absolute neutrophil count &lt; 500/ uL b. Platelet count &lt; 20,000/ uL c. Absolute reticulocyte count &lt; 60,000/ uL . Age &gt; 2 year old ii . Weight &gt; 9 kg . Diagnosis Fanconi 's anemia ii . Evidence clonal disorder cytogenetics . Patients severe neutropenia ( ANC &lt; 200 /uL ) exclude iii . Failure BMT iv . Prior immunosuppressive therapy ATG , ALG , alemtuzumab , high dose cyclophosphamide v. Infection adequately respond appropriate therapy vi . Serologic evidence HIV infection vii . Failure discontinue herbal supplement Other alternative approach treatment within 2 week enrolment viii . Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient 's ability tolerate protocol therapy , death within 710 day likely ix . History carcinoma consider cure ( except local cervical , basal cell , squamous cell ) x . Current pregnancy , unwillingness take oral contraceptive refrain pregnancy childbearing potential xi . Not able understand investigational nature study give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pancytopenia</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>ATG</keyword>
	<keyword>Cyclosporin</keyword>
</DOC>